vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and SOLAREDGE TECHNOLOGIES, INC. (SEDG). Click either name above to swap in a different company.
SOLAREDGE TECHNOLOGIES, INC. is the larger business by last-quarter revenue ($335.4M vs $180.9M, roughly 1.9× AVANOS MEDICAL, INC.). AVANOS MEDICAL, INC. runs the higher net margin — -0.7% vs -39.4%, a 38.7% gap on every dollar of revenue. On growth, SOLAREDGE TECHNOLOGIES, INC. posted the faster year-over-year revenue change (70.9% vs 0.7%). SOLAREDGE TECHNOLOGIES, INC. produced more free cash flow last quarter ($43.3M vs $21.3M). Over the past eight quarters, SOLAREDGE TECHNOLOGIES, INC.'s revenue compounded faster (28.1% CAGR vs 4.4%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
SolarEdge Technologies, Inc. is an Israeli company that developed a DC optimized inverter system.
AVNS vs SEDG — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $335.4M |
| Net Profit | $-1.3M | $-132.1M |
| Gross Margin | 47.5% | 22.2% |
| Operating Margin | 1.4% | -14.4% |
| Net Margin | -0.7% | -39.4% |
| Revenue YoY | 0.7% | 70.9% |
| Net Profit YoY | 99.7% | 54.0% |
| EPS (diluted) | $-0.02 | $-2.21 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $180.9M | $335.4M | ||
| Q3 25 | $177.8M | $340.2M | ||
| Q2 25 | $175.0M | $289.4M | ||
| Q1 25 | $167.5M | $219.5M | ||
| Q4 24 | $179.6M | $196.2M | ||
| Q3 24 | $170.4M | $235.4M | ||
| Q2 24 | $171.7M | $265.4M | ||
| Q1 24 | $166.1M | $204.4M |
| Q4 25 | $-1.3M | $-132.1M | ||
| Q3 25 | $-1.4M | $-50.1M | ||
| Q2 25 | $-76.8M | $-124.7M | ||
| Q1 25 | $6.6M | $-98.5M | ||
| Q4 24 | $-397.3M | $-287.4M | ||
| Q3 24 | $4.3M | $-1.2B | ||
| Q2 24 | $1.8M | $-130.8M | ||
| Q1 24 | $-900.0K | $-157.3M |
| Q4 25 | 47.5% | 22.2% | ||
| Q3 25 | 48.4% | 21.2% | ||
| Q2 25 | 52.6% | 11.1% | ||
| Q1 25 | 53.6% | 8.0% | ||
| Q4 24 | 54.6% | -57.2% | ||
| Q3 24 | 54.5% | -309.1% | ||
| Q2 24 | 55.7% | -4.1% | ||
| Q1 24 | 57.1% | -12.8% |
| Q4 25 | 1.4% | -14.4% | ||
| Q3 25 | 0.1% | -10.3% | ||
| Q2 25 | -42.6% | -39.9% | ||
| Q1 25 | 6.1% | -46.8% | ||
| Q4 24 | -233.0% | -134.4% | ||
| Q3 24 | 7.0% | -471.8% | ||
| Q2 24 | 3.7% | -60.4% | ||
| Q1 24 | 2.4% | -85.0% |
| Q4 25 | -0.7% | -39.4% | ||
| Q3 25 | -0.8% | -14.7% | ||
| Q2 25 | -43.9% | -43.1% | ||
| Q1 25 | 3.9% | -44.9% | ||
| Q4 24 | -221.2% | -146.5% | ||
| Q3 24 | 2.5% | -522.8% | ||
| Q2 24 | 1.0% | -49.3% | ||
| Q1 24 | -0.5% | -77.0% |
| Q4 25 | $-0.02 | $-2.21 | ||
| Q3 25 | $-0.03 | $-0.84 | ||
| Q2 25 | $-1.66 | $-2.13 | ||
| Q1 25 | $0.14 | $-1.70 | ||
| Q4 24 | $-8.64 | $-5.00 | ||
| Q3 24 | $0.09 | $-21.58 | ||
| Q2 24 | $0.04 | $-2.31 | ||
| Q1 24 | $-0.02 | $-2.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $493.2M |
| Total DebtLower is stronger | $90.3M | — |
| Stockholders' EquityBook value | $778.2M | $427.5M |
| Total Assets | $1.1B | $2.2B |
| Debt / EquityLower = less leverage | 0.12× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.8M | $493.2M | ||
| Q3 25 | $70.5M | $498.6M | ||
| Q2 25 | $90.3M | $758.0M | ||
| Q1 25 | $97.0M | $651.6M | ||
| Q4 24 | $107.7M | $585.9M | ||
| Q3 24 | $89.0M | $678.8M | ||
| Q2 24 | $92.2M | $689.8M | ||
| Q1 24 | $75.8M | $680.6M |
| Q4 25 | $90.3M | — | ||
| Q3 25 | $93.4M | — | ||
| Q2 25 | $95.7M | — | ||
| Q1 25 | $98.0M | — | ||
| Q4 24 | $125.3M | — | ||
| Q3 24 | $152.6M | — | ||
| Q2 24 | $164.9M | — | ||
| Q1 24 | $167.2M | — |
| Q4 25 | $778.2M | $427.5M | ||
| Q3 25 | $778.0M | $479.8M | ||
| Q2 25 | $776.3M | $513.2M | ||
| Q1 25 | $839.4M | $594.2M | ||
| Q4 24 | $828.5M | $658.3M | ||
| Q3 24 | $1.2B | $930.9M | ||
| Q2 24 | $1.2B | $2.1B | ||
| Q1 24 | $1.2B | $2.2B |
| Q4 25 | $1.1B | $2.2B | ||
| Q3 25 | $1.1B | $2.2B | ||
| Q2 25 | $1.0B | $2.5B | ||
| Q1 25 | $1.1B | $2.5B | ||
| Q4 24 | $1.2B | $2.6B | ||
| Q3 24 | $1.7B | $2.8B | ||
| Q2 24 | $1.7B | $3.9B | ||
| Q1 24 | $1.7B | $4.2B |
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.13× | — | ||
| Q1 24 | 0.14× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $52.6M |
| Free Cash FlowOCF − Capex | $21.3M | $43.3M |
| FCF MarginFCF / Revenue | 11.8% | 12.9% |
| Capex IntensityCapex / Revenue | 3.8% | 2.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | $80.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.2M | $52.6M | ||
| Q3 25 | $14.0M | $25.6M | ||
| Q2 25 | $6.8M | $-7.8M | ||
| Q1 25 | $25.7M | $33.8M | ||
| Q4 24 | $57.9M | $37.8M | ||
| Q3 24 | $23.0M | $-89.3M | ||
| Q2 24 | $27.8M | $-44.8M | ||
| Q1 24 | $-8.0M | $-217.0M |
| Q4 25 | $21.3M | $43.3M | ||
| Q3 25 | $7.0M | $22.8M | ||
| Q2 25 | $-4.2M | $-9.1M | ||
| Q1 25 | $19.0M | $23.7M | ||
| Q4 24 | $53.1M | $25.5M | ||
| Q3 24 | $20.0M | $-136.7M | ||
| Q2 24 | $21.9M | $-67.0M | ||
| Q1 24 | $-12.1M | $-243.4M |
| Q4 25 | 11.8% | 12.9% | ||
| Q3 25 | 3.9% | 6.7% | ||
| Q2 25 | -2.4% | -3.1% | ||
| Q1 25 | 11.3% | 10.8% | ||
| Q4 24 | 29.6% | 13.0% | ||
| Q3 24 | 11.7% | -58.1% | ||
| Q2 24 | 12.8% | -25.2% | ||
| Q1 24 | -7.3% | -119.1% |
| Q4 25 | 3.8% | 2.8% | ||
| Q3 25 | 3.9% | 0.8% | ||
| Q2 25 | 6.3% | 0.4% | ||
| Q1 25 | 4.0% | 4.6% | ||
| Q4 24 | 2.7% | 6.2% | ||
| Q3 24 | 1.8% | 20.1% | ||
| Q2 24 | 3.4% | 8.4% | ||
| Q1 24 | 2.5% | 12.9% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.89× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 5.35× | — | ||
| Q2 24 | 15.44× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
SEDG
| Other | $197.7M | 59% |
| Europe Except Netherlands | $99.4M | 30% |
| Others | $38.2M | 11% |
